The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
-
* Corresponding author: Robert Z Orlowski R_Orlowski@med.unc.edu
Breast Cancer Res 2003, 5:1-7 doi:10.1186/bcr460
See other articles in this series, http://breast-cancer-research.com/articles/series.asp?rqs=hynes2
Accesses
- Last 30 days: 57 accesses
- Last 365 days: 826 accesses
- All time: 8731 accesses
Cited by
BioMed Central: 2 citations
|
Research article
CIP2A is a target of bortezomib in human triple negative breast cancer cells Ling-Ming Tseng, Chun-Yu Liu, Kung-Chi Chang, Pei-Yi Chu, Chung-Wai Shiau, Kuen-Feng Chen Breast Cancer Research 2012, 14:R68 (26 April 2012) |
|
Research article
BU-32: a novel proteasome inhibitor for breast cancer Joseph K Agyin, Bindu Santhamma, Hareesh B Nair, Sudipa S Roy, Rajeshwar R Tekmal Breast Cancer Research 2009, 11:R74 (12 October 2009) The novel proteasome inhibitor, BU-32, exhibits strong cytotoxic and growth inhibitory effects in cultured cell lines and xenografts, pointing to its potential use as a breast cancer treatment.
|
